Basilea Pharmaceutica
Basilea is a Swiss company now focused on anti-infectives that ran phase 3 cancer trials of the FGFR inhibitor derazantinib and the tumour checkpoint controller lisavanbulin before divesting its oncology work in 2022.
Overview
Basilea Pharmaceutica, based near Basel and listed on the SIX Swiss Exchange, markets the antifungal isavuconazole and the antibiotic ceftobiprole. Its oncology portfolio, the FGFR inhibitor derazantinib in cholangiocarcinoma and urothelial cancer and the microtubule-targeting lisavanbulin in glioblastoma, was wound down in 2022 when the company decided to concentrate on anti-infectives and sought partners for the cancer assets. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- CompanyHangzhou Hanx Biopharmaceuticals
Shares Biliary tract cancer (cholangiocarcinoma), Glioma & glioblastoma and the tag ctgov-sponsor.
- CompanyPhotocure
Shares Bladder & urothelial cancer and the tag ctgov-sponsor.
- CompanySuzhou Forlong Biotechnology
Shares Bladder & urothelial cancer and the tag ctgov-sponsor.
- CompanyAveta Biomics
Shares Glioma & glioblastoma and the tag ctgov-sponsor.
- CompanyTiumBio
Shares Biliary tract cancer (cholangiocarcinoma) and the tag ctgov-sponsor.
- CompanyInovio Pharmaceuticals
Shares Glioma & glioblastoma and the tag ctgov-sponsor.
- CompanyMabwell (Shanghai) Bioscience
Shares Bladder & urothelial cancer and the tag ctgov-sponsor.
- CompanyPhilogen S.p.A.
Shares Glioma & glioblastoma and the tag ctgov-sponsor.